Kyntra Bio (KYNB) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kyntra Bio is the larger company by market cap ($6.3 million vs $5.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | XCUR |
|---|---|---|
| Share price | $1.56 | $0.9001 |
| Market cap | $6.32M | $5.89M |
| 1-day change | -13.33% | -12.82% |
| YTD return | -82.23% | — |
| 1-year return | -81.47% | — |
| 5-year return | -99.49% | — |
| EPS (TTM) | $-4.35 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.44M | $0 |
| Revenue growth (YoY) | -78.26% | -100.00% |
| Net income (latest FY) | $183.45M | $-4.95M |
| Gross margin | 91.37% | — |
| Operating margin | -712.66% | — |
| Net margin | 2848.63% | — |
| 52-week high | $10.47 | $9.48 |
| 52-week low | $1.56 | $0.777 |
| Distance from 52-week high | -85.10% | -90.51% |
| Analyst consensus | none | — |
| Avg. price target upside | +2442.95% | — |
| Average volume | 29.96K | 53.56K |
| Shares outstanding | 4.05M | 6.55M |
| Employees | 34 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kyntra Bio grew revenue faster in its latest fiscal year (-78.26% vs -100.00%).
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
KYNB vs XCUR FAQ
Which is bigger, Kyntra Bio or Exicure?
Kyntra Bio (KYNB) is larger, with a market capitalization of $6.32M compared with $5.89M for Exicure (XCUR).
Are Kyntra Bio and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.